Trials / Terminated
TerminatedNCT01847222
An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Prolong Pharmaceuticals · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
Safety assessment of SANGUINATE™ in Healthy Volunteers.
Detailed description
Safety and Pharmacokinetic assessment in ascending doses of SANGUINATE™ in Healthy Volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SANGUINATE™ | PEG-bHb-CO |
| DRUG | Normal Saline Solution | Placebo |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2014-05-01
- Completion
- 2014-08-01
- First posted
- 2013-05-06
- Last updated
- 2015-01-06
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT01847222. Inclusion in this directory is not an endorsement.